Ann: Options exercise, page-10

To think holders of IHL and IHLOB are not selling the heads to fund their IHLOB is niaive.

I believe many have been selling which is why we have weakness ATM.

I think we will start to a rerate once the IHLOB conversions are complete.

Im hanging in. Personally I think this stock has one of the best and smartest boards going.

Covid has slowed the progress, but nothing else has changed.

With 1 successful human trial, i see this rerating dramatically. The board have been smar, patenting the drug formulations prior to testing.

I can see a big pharma buying us out at some point in the next 1-2 years at $1 plus.

And i think Sud will convert his 200,000,000 options @ 20c this time next year.

This is just my guestimate on where IHL is going moving forward. Id love to see an update from the company soon as to how we are progressing with the multiple of human trials, the sleep apnea for starters. That IMHO is a complete game changer.

GLTAH